Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Inventory (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Inventory for 3 consecutive years, with $281000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Inventory rose 21.65% to $281000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $281000.0, a 21.65% increase, with the full-year FY2025 number at $281000.0, up 21.65% from a year prior.
  • Inventory was $281000.0 for Q4 2025 at Lexicon Pharmaceuticals, up from $158000.0 in the prior quarter.
  • In the past five years, Inventory ranged from a high of $636000.0 in Q3 2024 to a low of $158000.0 in Q3 2025.
  • A 3-year average of $333000.0 and a median of $281000.0 in 2025 define the central range for Inventory.
  • Peak YoY movement for Inventory: soared 240.12% in 2024, then plummeted 75.16% in 2025.
  • Lexicon Pharmaceuticals' Inventory stood at $381000.0 in 2023, then crashed by 39.37% to $231000.0 in 2024, then grew by 21.65% to $281000.0 in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Inventory are $281000.0 (Q4 2025), $158000.0 (Q3 2025), and $168000.0 (Q2 2025).